Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action

Executive Summary

FDA enters the fourth quarter with at least 28 pending applications with October user fee deadlines, including seven new molecular entities and one new biologic
Advertisement

Related Content

FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III
FDA User Fee Review Staff Hiring To Be Lower Than Projected Under PDUFA III
Provigil Likely To Add Two New Claims; Broad Sleepiness Indication May Wait
Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.
Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.
Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA
Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended
New Drug Approvals In 2003 Could Include Four HIV Agents
New Drug Approvals In 2003 Could Include Four HIV Agents
Advertisement
UsernamePublicRestriction

Register

PS042582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel